Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe, Handok - LARVOL DELTA

Teneligliptin alleviates acute kidney injury by exerting anti-ferroptotic effects on renal tubules (ERA 2025) - No abstract available

Acute Kidney Injury • Nephrology • Renal Disease

Failure Mode Effects Analysis and Design of Experiments to Sensitive and Sustainable Microwave-Aided Spectrofluorophotometric Estimation of Teneligliptin and Method's Chlor-Tox Scale and Blue Applicability Grade Index Assessment. (PubMed, Luminescence) - "The fluorescent product that was derivatized using microwaves was separated and studied using mass spectrometry. After greenness and whiteness profile assessment, researchers discovered that the suggested approach to teneligliptin estimate was eco-friendly, precise, robust, rapid, economical, and easy to apply."

Journal • Hypoglycemia

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Handok Inc.

New P1 trial

Analytical Methods for Estimating Metformin Hydrochloride, Pioglitazone and Teneligliptin in Diabetes Management: a Comprehensive Review. (PubMed, J Chromatogr Sci) - "By offering a comprehensive assessment of the analytical methods used for the estimation of Metformin, Pioglitazone and Teneligliptin for diabetes treatment, this review serves as a valuable resource for researchers, clinicians and pharmaceutical scientists. It aids in selecting the most suitable analytical method for specific applications, contributing to the continuous improvement of diabetes management and treatment."

Journal • Review • Diabetes • Infectious Disease • Metabolic Disorders

HD-MP-106: Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Handok Inc. | Trial completion date: Nov 2024 ➔ Jun 2024 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date

In-vivo Microwave-aided Spectrofluorimetric Characterization of Teneligliptin-loaded Solid Dispersion Adsorbate Using Quality by Design Approach. (PubMed, Anal Biochem) - "The method demonstrated environmental sustainability, robustness, sensitivity, cost-effectiveness, and user-friendliness when evaluated using white analytical chemistry approaches. It provided a sensitive and green alternative to existing hyphenated techniques for nanogram-level teneligliptin detection in pharmacokinetic studies."

Journal • Preclinical

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) (clinicaltrials.gov) - P4 | N=39 | Completed | Sponsor: Handok Inc. | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin (clinicaltrials.gov) - P=N/A | N=2983 | Completed | Sponsor: Handok Inc. | Unknown status ➔ Completed | N=4875 ➔ 2983

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

TERA 305: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin (clinicaltrials.gov) - P3 | N=214 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed | Trial completion date: May 2025 ➔ Jun 2024

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pleiotropic effect of teneligliptin versus glimepiride add-on therapy on hs-CRP and cardiorenal parameters in Indian type 2 diabetes patients: An open-labeled randomized controlled trial. (PubMed, Perspect Clin Res) - "The objective of the study was to estimate the pleiotropic effect of teneligliptin on high-sensitivity C-reactive protein (hs-CRP) levels and some cardiorenal parameters in comparison to glimepiride, both as add-on therapy to metformin. Teneligliptin add-on resulted in favorable effects on hs-CRP levels and comparable effects on cardiorenal parameters compared to glimepiride add-on therapy at 12-weeks end.This trial has been prospectively registered in CTRI (Clinical Trials Registry of India). Registration number: CTRI/2021/08/035342."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

TERA 304: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin (clinicaltrials.gov) - P3 | N=235 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Apr 2024 | Trial primary completion date: Nov 2024 ➔ Apr 2024

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Which antidiabetic drugs do patients of T2DM prefer in India and why? A discrete choice experiment. (PubMed, J Family Med Prim Care) - "Out of the 87 evaluated participant choices, the most preferred drug was Glimepiride (51.7%), followed by Dapagliflozin (22.9%) and Teneligliptin (17.2%). Glimepiride was the most preferred option overall while the effect on weight was the most important attribute for patients in determining their preference. The study highlighted the importance of shared decisions and can guide practitioners in considering patient preferences when prescribing antidiabetic drugs."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies. (PubMed, World J Diabetes) - "Through the use of both in vivo and in vitro models, the study demonstrated that teneligliptin alleviates cardiac hypertrophy, reduces myocardial injury, and mitigates the inflammatory responses associated with DCM. These findings suggest that teneligliptin's cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation, positioning it as a promising therapeutic option for managing DCM in diabetic patients."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • NLRP3

Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis. (PubMed, Diabetes Obes Metab) - "In adults with type 2 diabetes, teneligliptin was most effective for HbA1c control, and vildagliptin for fasting blood glucose. No significant differences in serious adverse events were noted among DPP-4 inhibitors compared to placebo. Given the therapeutic significance of these findings, more studies are needed to explore this issue more thoroughly."

Journal • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. (PubMed, Cells) - "These results indicate SEMA's neuroprotective benefits against diabetic neuropathic pain, most likely by reducing inflammation and oxidative stress by inhibiting astrocyte and microglial activity. Our findings suggest that we can repurpose GLP-1 agonists as potent anti-hyperalgesic and anti-inflammatory drugs to treat neuropathic pain without serious side effects."

Journal • CNS Disorders • Diabetic Neuropathy • Genetic Disorders • Inflammation • Metabolic Disorders • Neuralgia • Obesity • Pain • Psychiatry • Type 2 Diabetes Mellitus

Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study). (PubMed, Front Endocrinol (Lausanne)) - "On the other hand, it is likely that alleviation of β-cell dysfunction is more effective with luseogliflozin compared to tenegliptin. https://rctportal.niph.go.jp/en, identifier jRCTs061190008."

Clinical • Journal • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. (PubMed, World J Diabetes) - "Given that the NLRP3 inflammasome plays a crucial role in the onset and progression of DCM, it presents a promising therapeutic target. Nevertheless, further clinical validation is required to ascertain the preventive and therapeutic efficacy of teneligliptin in DCM."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Metabolic Disorders • NLRP3

Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? (PubMed, World J Diabetes) - "These compounds may achieve this by elevating glucagon-like peptide-1 levels and potentially inhibiting the NLRP3 inflammasome. Further studies on teneligliptin in combination with other therapies targeting different aspects of DCM could be suggested for developing more effective treatment strategies to improve cardiovascular health in diabetic patients."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Metabolic Disorders • NLRP3

Investigation of Glucose Metabolism by Continuous Glucose Monitoring and Validation of Dipeptidyl Peptidase 4 Inhibitor Use in Patients with Myotonic Dystrophy Type 1. (PubMed, J Clin Med) - "The CGM identified potential early abnormalities in glucose metabolism in DM1. In the future, it will be crucial to explore effective methods for harnessing CGM and assessing it quantitatively in DM1."

Journal • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Muscular Dystrophy • Myotonic Dystrophy

Stability-Indicating Green HPLC Method for Fixed-Dose Tablets Containing Remogliflozin Etabonate and Teneligliptin: An AQbD Approach. (PubMed, Drug Dev Ind Pharm) - "The AGREE score of 0.65 supports its green applicability for tablet analysis in quality control. The AQbD-assisted RP-HPLC method developed in this study offers environmental friendliness, efficient separation with well-defined peaks, and simple mobile phase combination."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Diabetic cardiomyopathy: Emerging therapeutic options. (PubMed, World J Diabetes) - "A basic study by Zhang et al, in a recent issue of the World Journal of Diabetes elaborates the potential pathophysiological alterations and the therapeutic role of teneligliptin in diabetic mouse models with DbCM. Although this preliminary basic study might help to improve our understanding of DbCM and offer a potential new management option for patients with the disease, the positive results from such animal models might not always translate to clinical practice as the pathobiology of DbCM in humans could be different. However, such experimental studies can encourage more scientific efforts to find a better solution to treat patients with this enigmatic disease."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hypertension • Metabolic Disorders • Pain

Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy. (PubMed, World J Diabetes) - "Suppression of NOD-like receptor protein 3 inflammasome activity reduces the expression of cytokines, oxygen radicals and inflammation. These findings highlight teneligliptin as an anti-diabetic cardioprotective reagent."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Diabetic Neuropathy • Diabetic Retinopathy • Inflammation • Metabolic Disorders • Pain • Retinal Disorders

Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study. (PubMed, BMC Endocr Disord) - "Canagliflozin and teneligliptin have different effects on the dietary status of patients with Type 2 diabetes. Our result suggests that canagliflozin can manage blood glucose without weight gain, even with increased energy intake."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Triple-Arm, Prospective, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess Effect on FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg Compared with FDC of Sitagliptin 100 mg + Dapagliflozin 10 mg and FDC of Linagliptin 5 mg+ Empagliflozin 25 mg on 24-Hour Glucose . (ADA 2024) - "FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg & FDC of Linagliptin 5 mg + Empagliflozin 25 mg had significant improvement in CGM & Glycemic parameters."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus. (PubMed, Diabetes Res Clin Pract) - "The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods."

Journal • Monotherapy • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • IL6